PMID- 25404353
OWN - NLM
STAT- MEDLINE
DCOM- 20150507
LR  - 20220311
IS  - 1179-2019 (Electronic)
IS  - 1174-5878 (Print)
IS  - 1174-5878 (Linking)
VI  - 16
IP  - 6
DP  - 2014 Dec
TI  - Omalizumab in children.
PG  - 491-502
LID - 10.1007/s40272-014-0107-z [doi]
AB  - Omalizumab is a recombinant humanized monoclonal antibody that reduces levels of 
      circulating immunoglobulin E (IgE) and expression of IgE high-affinity receptors 
      on mast cells and basophils, interrupting the subsequent allergic inflammatory 
      cascade. Current indications for treatment with omalizumab in pediatric patients 
      are clearly defined and are confined to moderate-to-severe uncontrolled allergic 
      asthma and chronic spontaneous urticaria (CSU). Any other prescription can only 
      be off label. Data available from clinical trials conducted in children suggest 
      that omalizumab is clinically effective and generally well tolerated. Given its 
      mechanism of action, recent reports have suggested its possible clinical use in 
      other IgE-mediated disorders, such as allergic rhinitis, food allergy, and 
      anaphylaxis. In recent years, several studies have also investigated the possible 
      applications of omalizumab in a number of non IgE-mediated diseases. The aim of 
      the present review is to assess all applications of omalizumab as therapy in the 
      pediatric population. The approved indications--allergic asthma and CSU--are 
      reviewed. Moreover, further potential applications of omalizumab are discussed in 
      both IgE-mediated and non-IgE-mediated diseases.
FAU - Licari, Amelia
AU  - Licari A
AD  - Department of Pediatrics, University of Pavia, Fondazione IRCCS San Matteo, 
      Pavia, Italy.
FAU - Marseglia, Alessia
AU  - Marseglia A
FAU - Caimmi, Silvia
AU  - Caimmi S
FAU - Castagnoli, Riccardo
AU  - Castagnoli R
FAU - Foiadelli, Thomas
AU  - Foiadelli T
FAU - Barberi, Salvatore
AU  - Barberi S
FAU - Marseglia, Gian Luigi
AU  - Marseglia GL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Switzerland
TA  - Paediatr Drugs
JT  - Paediatric drugs
JID - 100883685
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Anti-Allergic Agents/*therapeutic use
MH  - Antibodies, Anti-Idiotypic/adverse effects/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/adverse effects/*therapeutic use
MH  - Asthma/*drug therapy
MH  - Child
MH  - Food Hypersensitivity
MH  - Humans
MH  - Immunoglobulin E/immunology
MH  - Omalizumab
MH  - Quality of Life
MH  - Urticaria/*drug therapy
PMC - PMC4250568
EDAT- 2014/11/19 06:00
MHDA- 2015/05/08 06:00
PMCR- 2014/11/18
CRDT- 2014/11/19 06:00
PHST- 2014/11/19 06:00 [entrez]
PHST- 2014/11/19 06:00 [pubmed]
PHST- 2015/05/08 06:00 [medline]
PHST- 2014/11/18 00:00 [pmc-release]
AID - 107 [pii]
AID - 10.1007/s40272-014-0107-z [doi]
PST - ppublish
SO  - Paediatr Drugs. 2014 Dec;16(6):491-502. doi: 10.1007/s40272-014-0107-z.